- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02361541
Determination of HCV Prevalence in a HIV Patient Cohort in Phnom Penh, Cambodia (HCV-Epi)
Determination of Hepatitis C Prevalence, Genetic Diversity and Treatment Eligibility in an HIV Patient Cohort in Phnom Penh, Cambodia
Hepatitis C (HCV) is an important global public health problem, disproportionately affecting HIV positive populations. Asia and Africa account for most of the co-infection burden, but access to HCV screening and treatment is still very limited. It is expected though, with the recent therapeutic advances and increasing global advocacy efforts, that HCV treatment should become a feasible option in the near future.
Sihanouk Hospital Center of HOPE (Phnom Penh, Cambodia) is catering for one of the largest HIV cohorts of the country, followed in an ambulatory settings. In this cohort, the prevalence of HCV co-infection will be determined, as well as HCV genotype diversity and the severity of liver disease. The researcher will also explore the performance of simple blood tests/panels as predictors of significant fibrosis and/or cirrhosis.
Patients will attend two study-visits. All adult patients of the HIV patient cohort of SHCH will be proposed HCV testing during their next HIV follow-up consultation, following the latest algorithm of the Centre for Disease Control (CDC) (May 2013). Anamnesis and clinical examination will focus, additionally to routine practice, on presence of general and HCV liver-disease related features. Laboratory analyses will include basic HIV tests (CD4), and tests for liver function such as Hepatitis B surface antigen (HbsAg) .
During the following routine HIV follow-up consultation, the results of HCV testing will be explained to the patient. If the patient is HCV negative, his/her study participation ends here. If currently infected with HCV, the clinician will repeat the HCV liver-disease (extra-hepatic & hepatic) related anamnesis and clinical examination, and prescribe additional blood tests for the non-invasive liver fibrosis/cirrhosis blood panel tests, liver and kidney function. Patients will moreover be asked to undergo a liver ultrasound and liver stiffness measurements.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Hepatitis C (HCV) is an important global public health problem, disproportionally affecting HIV positive populations. Asia and Africa account for most of the co-infection burden, but access to HCV screening and treatment is still very limited. The high cost and complexity of current diagnostic and treatment algorithms are major bottlenecks and the linked lack of accurate HCV prevalence estimates and treatment-need data do not allow for robust treatment advocacy and program planning. Cambodia is not an exception.
It is expected though, with the recent therapeutic advances and increasing global advocacy efforts, that HCV treatment should become a feasible option in the near future. Sihanouk Hospital Center of HOPE (Phnom Penh, Cambodia) is catering for one of the largest HIV cohorts of the country, and it is planning to engage in HCV treatment from 2014 2015 onwards, with a double objective of direct patient benefit and catalyst role at national level, as in the past when starting its antiretroviral (ARV) program.
Within this specific setting, the researchers plan to determine the prevalence of HCV co-infection, HCV genotype diversity and severity of liver disease in this HIV patient cohort, followed in an ambulatory setting. The researchers will also explore the performance of simple blood tests/panels as predictors of significant fibrosis and/or cirrhosis .
The current HCV diagnostic procedures (and tools), as applied in this study, are too expensive and resource-demanding to allow for scalability in resource limited settings. Thus, the researchers plan to set up during this study a biobank with samples of a clinically well described HIV patient population. These samples should allow constituting a well-balanced panel for evaluation of future 'more scalable' HCV diagnostic tools.
Patients will attend two study-visits. All adult patients of the HIV cohort will be proposed HCV testing during their next regular HIV follow-up consultation. HCV testing will follow the latest algorithm of the Centre for Disease Control (CDC) (May 2013). During this same consultation, anamnesis and clinical examination will focus, additionally to routine practice ,on presence of general and HCV liver-disease related features. Laboratory analyses will also include basic HIV (CD4), and tests for liver function such as Hepatitis B surface antigen (HbsAg).
During the following routine HIV follow-up consultation (2-3 months later), the results of HCV testing will be explained to the patient. If the patient is HCV negative, his/her study participation ends here. If currently infected with Hepatitis C, the clinician will repeat the HCV liver-disease (extra-hepatic & hepatic) related anamnesis and clinical examination and prescribe additional blood tests for the non-invasive liver fibrosis/cirrhosis blood panel tests, liver and kidney function. Patients will moreover be asked to undergo a liver ultrasound and liver stiffness measurements.
The biobank will be set up with left over biological samples (whole blood plasma and serum) and comprehensive clinical information of all patients who give additional consent for this scope. Both biological samples and clinical information will be coded, to ensure confidentiality.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Phnom Penh, Kambodža
- Sihanouk Hospital Center of HOPE (SHCH), Cambodia
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- Adult (> or = 18 years old)
- Documented HIV positive
- In regular HIV care follow-up (min. 2 consultations in the last six months prior to the study)
- Willing and able to provide written informed consent
Exclusion Criteria:
• HIV patients with currently taking Hepatitis C treatment or with a history of prior hepatitis C treatment
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
---|---|
HCV screening
All adult patients of an existing HIV cohort
|
HCV antibody screening, liver function tests, full blood count and HbsAg will performed.
Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping).
For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Seroprevalence of HCV infection
Aikaikkuna: Baseline
|
Seroprevalence of HCV infection in the HIV patient cohort
|
Baseline
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Proportion of current HCV infection
Aikaikkuna: Baseline
|
Proportion of currently infected with HCV among the HCV-IgG positive HIV patients
|
Baseline
|
Proportion of HCV false-positives
Aikaikkuna: Baseline
|
Proportion of HCV biologically false-positives among HCV-IgG positive screening
|
Baseline
|
HCV genotypes
Aikaikkuna: Baseline
|
Proportions of different HCV genotypes
|
Baseline
|
Severity of liver disease in HCV patients
Aikaikkuna: Baseline
|
To determine the severity of liver disease by transient elastography in this coinfected cohort
|
Baseline
|
HCV diagnostic accuracy
Aikaikkuna: Baseline
|
To compare the diagnostic accuracy of commonly available blood panel tests for fibrosis staging in this coinfected cohort, with liver stiffness measurement (considered as reference standard).
|
Baseline
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Tutkijat
- Opintojohtaja: Anja De Weggheleire, MD, Institute of Tropical Medicine, Antwerp, Belgium
- Päätutkija: An Sokkab, MD, Sihanouk Hospital Center of HOPE (SHCH), Cambodia
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- HCV-Epi
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset C-hepatiitti
-
Dokuz Eylul UniversityEge UniversityValmisMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CTurkki
-
Meir Medical CenterValmisUuden tekniikan kehittäminen digitaalisten stereooptisten levykuvien C/D-suhteen mittaamiseksi | Intraobserver C/D-mittausten toistettavuus | Interobserver vaihtelevuus C/D mittaukset
-
Tripep ABInovio PharmaceuticalsTuntematonKrooninen hepatiitti C -virusinfektioRuotsi
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsPeruutettuKrooninen hepatiitti C -virusinfektioIsrael
-
Hadassah Medical OrganizationTuntematonKrooninen hepatiitti C -virusinfektioIsrael
-
University College CorkDupont Applied BiosciencesRekrytointi
-
Beni-Suef UniversityValmisKrooninen hepatiitti C -virusinfektioEgypti
-
Trek Therapeutics, PBCValmisKrooninen hepatiitti C | Hepatiitti C genotyyppi 1 | C-hepatiitti (HCV) | Hepatiitti C -virusinfektioYhdysvallat, Uusi Seelanti
-
Trek Therapeutics, PBCValmisKrooninen hepatiitti C | C-hepatiitti (HCV) | Hepatiitti C genotyyppi 4 | Hepatiitti C -virusinfektioYhdysvallat
Kliiniset tutkimukset HCV screening
-
Memorial University of NewfoundlandValmisTupakointi | Hypertensio | Diabetes mellitus | Liikunta | Stressi, psykologinen | Dyslipidemiat | Kardiovaskulaarinen riskitekijäKanada
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; Fondation... ja muut yhteistyökumppanitTuntematon
-
Institut Universitari DexeusValmisHedelmättömyys | Implantaatiota edeltävä geneettinen seulontaEspanja
-
University of New MexicoRekrytointiHaitalliset lapsuuden kokemuksetYhdysvallat
-
Texas State University, San MarcosNational Institute on Disability, Independent Living, and Rehabilitation...RekrytointiAutismispektrihäiriöYhdysvallat
-
Asociacion para el Estudio del HigadoMerck Sharp & Dohme LLCTuntematon
-
BDH-Klinik Hessisch OldendorfRekrytointiAivohalvaus | Neurologinen häiriö | Kognitio | MagnesiumSaksa
-
University of PittsburghNational Institute of Mental Health (NIMH); Kaiser Foundation Research InstituteValmis
-
Washington University School of MedicineNational Institute on Minority Health and Health Disparities (NIMHD)ValmisOnkologia | Rintasyövän seulonta | Mammografia | Ennaltaehkäisevä lääketiedeYhdysvallat
-
Denver Health and Hospital AuthorityBoston University; Johns Hopkins University; Boston Medical Center; University... ja muut yhteistyökumppanitAktiivinen, ei rekrytointi